{"url_path":"/sec/dyai/8-k/2026-06-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ****Regulation","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1213809/0001493152-26-028700-index.html","accession_number":"0001493152-26-028700","cik":"0001213809","ticker":"DYAI","issuer_name":"DYADIC INTERNATIONAL INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1213809/0001493152-26-028700-index.html","primary_entity_key":"0001213809","primary_entity_name":"DYADIC INTERNATIONAL INC"},"word_count":148,"has_tables":true,"body_markdown":"**Item\n7.01.****Regulation\nFD Disclosure.**\n\n \n\nOn\nJune 15, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) issued a press release titled “Dyadic\nHighlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption”.\nThe press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe\ninformation in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall\nnot be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange\nAct”), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any\nfiling under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference\nin such a filing."}